Avoid use at the same time or right after meals since sleep induction may be delayed. Patients w/ organic brain disorders; moderate & severe resp function disorders. Consider the necessity of continuing use when symptoms improve & ensure that Dayvigo is not aimlessly administered. Sleep paralysis, hypnagogic/hypnopompic hallucinations & mild cataplexy-like symptoms. Worsening of depression/suicidal ideation; immediately evaluate emergence of any new behavioural sign or symptom of concern. Immediately discontinue use if patient experiences complex sleep behaviours including sleep-walking, sleep-driving & engaging in other activities while not fully awake. Concomitant use w/ other drugs for insomnia. May induce drowsiness, impairment of attention, concentration & reflex movements; avoid potentially hazardous activities (eg, operating machinery or driving a motor vehicle). Mild & moderate hepatic impairment. Severe renal impairment. Pregnant or possibly pregnant women. Avoid use in lactating women; stop breastfeeding when there is no other choice but to administer the drug. Childn. Elderly.
Sign Out
